1 week Ago By Defense World Staff
Shares of MediciNova, Inc. ( NASDAQ:MNOV – Get Free Report ) passed above its 200-day moving average during trading on Wednesday . The stock has a 200-day moving average of $1.
69 and traded as high as $2.19. MediciNova shares last traded at $2.
10, with a volume of 30,965 shares changing hands. Analyst Upgrades and Downgrades Several brokerages have issued reports on MNOV. D.
Boral Capital started coverage on MediciNova in a research report on Monday, December 2nd. They issued a “buy” rating and a $9.00 target price on the stock.
StockNews.com began coverage on shares of MediciNova in a report on Thursday. They issued a “hold” rating on the stock.
Read Our Latest Stock Analysis on MediciNova MediciNova Stock Down 0.5 % Institutional Inflows and Outflows An institutional investor recently bought a new position in MediciNova stock. Jane Street Group LLC acquired a new position in MediciNova, Inc.
( NASDAQ:MNOV – Free Report ) in the third quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor acquired 14,138 shares of the biopharmaceutical company’s stock, valued at approximately $30,000. 9.
90% of the stock is currently owned by institutional investors. MediciNova Company Profile ( Get Free Report ) MediciNova, Inc, a biopharmaceutical company, focuses on developing novel and small molecule therapeutics for the treatment of serious diseases with unmet medical needs in the United States. It is developing MN-166 (ibudilast), an oral anti-inflammatory and neuroprotective agent for treating neurological and other disorders, such as primary and secondary progressive multiple sclerosis, amyotrophic lateral sclerosis, chemotherapy-induced peripheral neuropathy, degenerative cervical myelopathy, glioblastoma, and substance dependence and addiction, as well as prevention of acute respiratory distress syndrome, and long COVID.
See Also Five stocks we like better than MediciNova Insider Selling Explained: Can it Inform Your Investing Choices? Work and Play: Investing in the Rise of Bleisure Travel The Risks of Owning Bonds Top Dividend Stocks to Buy Now as Bond Yields Could Lower How to Find Undervalued Stocks SAP: AI Tailwinds Accelerating Enterprise Cloud Business Receive News & Ratings for MediciNova Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for MediciNova and related companies with MarketBeat.com's FREE daily email newsletter ..
